BRAIN Biotech AG takes next step to optimize group structure

EQS-News: BRAIN Biotech AG / Key word(s): Miscellaneous
BRAIN Biotech AG takes next step to optimize group structure

16.04.2024 / 11:20 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

BRAIN Biotech AG takes next step to optimize group structure

BRAIN Biotech Group will merge AnalytiCon Discovery GmbH into BRAIN Biotech
AG in order to further optimize and simplify the Group structure.

Zwingenberg, Germany, 16 April 2024 - The Management Board of BRAIN Biotech
AG, with the approval of the Supervisory Board, has resolved to merge
AnalytiCon Discovery GmbH with BRAIN Biotech AG. AnalytiCon Discovery GmbH,
based in Potsdam, Germany, is already a fully owned subsidiary of the BRAIN
Biotech Group.

This legal reorganization will further optimize and simplify the structure
of the BRAIN Biotech Group. The operational business of both units remains
unaffected and will continue unchanged at the respective locations.

Michael Schneiders, CFO of BRAIN Biotech AG, comments on the merger: "Last
year we have merged our product business under the umbrella of Biocatalysts.
We are now taking the next logical step by legally combining our scientific
services in the BioScience business segment under the umbrella of the BRAIN
Biotech AG. This will not result in any noticeable changes for our employees
at both locations or for our business partners."

Further documents on the resolved merger of BRAIN Biotech AG with AnalytiCon
Discovery GmbH can be viewed on the company's website at
https://www.brain-biotech.com/merger-information.

+++

About BRAIN Biotech

BRAIN Biotech AG is a leading European supplier of biobased products and
solutions such as enzymes and proteins, microbial production strains,
natural compounds and biotechnological solutions for more sustainable
industrial processes. The company focuses on the fields of nutrition, health
and environment.

BRAIN Biotech AG is the parent company of the international BRAIN Biotech
Group. The Group's business activities are divided into three segments: The
BioProducts segment comprises the product business with specialty enzymes
and other proteins, for which the Group operates fermentation facilities in
the United Kingdom and production facilities in continental Europe and the
United States. The BioScience segment offers research-intensive custom
solutions based on enzyme technology, strain development, bioprocess
development and natural product screening. The BioIncubator segment conducts
its own R&D projects or those initiated with partners with high value-added
potential. A particularly promising incubator project is the development of
the Company's own CRISPR-based gene editing technology platform, which is
currently being established and expanded by Akribion Genomics (in foundation
planning).

Through its own R&D activities, BRAIN Biotech Group is continuously
expanding its product portfolio in the field of specialty enzymes and small
molecules. The latter are the starting point for screenings, e.g. for novel
drug candidates for pharmaceutical applications.

BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt
Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities
identification number: ISIN DE0005203947 / WKN 520394). The company employs
approximately 330 people and generated revenues of EUR 55.3 million in the
fiscal year 2022/23.

For more information, please visit: https://www.brain-biotech.com, LinkedIn,
Threads and YouTube.

About AnalytiCon Discovery

AnalytiCon Discovery GmbH is a research and development company with many
years of expertise in natural product chemistry. The Potsdam-based company
specializes in small molecule compounds and offers customers from the
pharmaceutical, cosmetics, food and agricultural sectors the development of
substance libraries, the identification of active ingredients and their
synthetic optimization as well as the production of active ingredients on a
commercial scale. AnalytiCon has been part of the BRAIN Biotech Group since
2013. Further information: www.ac-discovery.com

Contact Media BRAIN Biotech

Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Contact Investor Relations BRAIN Biotech

Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN Biotech AG, and are based on information currently available to the
management.

Forward-looking statements are no guarantees of future performance, and
entail both known and unknown risks as well as uncertainties that could
cause actual results, performance or events to differ materially from those
expressed or implied in such statements. Numerous factors exist that could
influence the future performance of and future developments at BRAIN Biotech
AG and the BRAIN Biotech Group. Such factors include, but are not limited
to, changes in the general economic and competitive environment, risks
associated with capital markets, currency exchange rate fluctuations,
changes in international and national laws and regulations, in particular
with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any
forward-looking statements.


---------------------------------------------------------------------------

16.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        BRAIN Biotech AG
                   Darmstädter Straße 34-36
                   64673 Zwingenberg
                   Germany
   Phone:          +49 (0) 62 51 / 9331-0
   Fax:            +49 (0) 62 51 / 9331-11
   E-mail:         ir@brain-biotech.com
   Internet:       www.brain-biotech.com
   ISIN:           DE0005203947
   WKN:            520394
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1881585

End of News EQS News Service
---------------------------------------------------------------------------

1881585 16.04.2024 CET/CEST